Equine Parvovirus-Hepatitis in Horses: Causes, Testing, and Risk

Equine parvovirus-hepatitis, often shortened to EqPV-H, is a virus that targets the liver. It is now strongly associated with equine serum hepatitis, a condition many horse professionals still know as Theiler's disease. In some horses, infection causes no outward illness at all. In others, it can trigger acute hepatitis and, in the most serious cases, fulminant liver failure.

What makes this condition challenging is that a positive test does not always mean a horse is currently sick from the virus. Many horses appear healthy or have only temporary liver enzyme changes. According to AAEP guidance, only a small percentage of infected horses go on to develop obvious clinical liver disease.

When disease does occur, it can be severe and fast-moving. Horses may become dull, stop eating, develop jaundice, or show neurologic changes related to liver failure and high ammonia levels. Because the liver has a large reserve capacity, signs may not appear until damage is already significant.

For pet parents, the key takeaway is this: EqPV-H is a real but variable risk. Some horses clear or tolerate infection with little consequence, while others need urgent supportive care. Your vet can help interpret test results in the context of symptoms, bloodwork, and recent exposure history.

EqPV-H is caused by infection with a single-stranded DNA parvovirus that has a strong preference for liver tissue. Two broad transmission patterns are recognized: biologic transmission and non-biologic transmission.

Biologic transmission happens when a horse receives an equine-origin product contaminated with the virus. AAEP lists examples such as tetanus antitoxin, botulinum antitoxin, Streptococcus equi antiserum, pregnant mare serum, equine plasma products, and some allogeneic stem cell preparations. In these cases, clinical liver disease has been reported about 4 to 13 weeks after exposure.

Non-biologic transmission also occurs, but it is less clearly understood. Cases have appeared in horses with no recent history of receiving biologic products. Seasonal clustering in late summer to early fall has raised concern about a possible insect-related route, though that has not been fully proven. Needle sharing between horses is also considered a risk.

Importantly, infection is not the same as illness. Many horses remain asymptomatic, and some may only have temporary increases in liver enzymes. Research is still evolving, so your vet may also consider other liver insults, such as toxins or concurrent disease, when deciding how much EqPV-H is contributing in an individual horse.

Diagnosis usually starts with a history and physical exam, especially questions about recent use of equine biologic products, herd exposure, and timing of symptoms. Your vet will typically run bloodwork, including a chemistry panel and liver-focused values. Horses with clinical hepatitis often have increased liver enzymes such as GGT, AST, SDH, and GLDH, along with abnormal bile acids and sometimes elevated blood ammonia.

To look for the virus itself, vets can submit PCR testing on serum, EDTA plasma, whole blood, or liver biopsy samples. AAEP notes that for acute cases with high viral load, these sample types can be useful for diagnosis. Cornell's Animal Health Diagnostic Center offers EqPV-H PCR testing, and published fee schedules have listed the assay itself around $41, though total diagnostic cost is higher once farm call, exam, blood draw, chemistry testing, shipping, and interpretation are included.

A positive PCR alone does not prove the virus is the only cause of liver disease. Your vet may recommend repeat bloodwork, serial PCR monitoring, abdominal ultrasound, or liver biopsy to better understand severity and rule out other causes such as toxic injury, chronic fibrosis, or other hepatotropic viruses. In some fulminant cases, liver size can be so reduced that ultrasound guidance is needed before biopsy is considered.

In practical terms, diagnosis is about building the whole picture: clinical signs, liver values, exposure history, and targeted viral testing. That is why two horses with the same PCR result may be managed very differently.

There is no vaccine for EqPV-H at this time, so prevention centers on reducing known exposure risks. The most important step is to use autogenous biologics when appropriate or USDA-licensed equine biologic products that have been PCR-tested and confirmed free of EqPV-H. If your horse needs plasma, antitoxin, or another equine-origin product, ask your vet how that product is sourced and screened.

Good injection hygiene also matters. Never share needles or syringes between horses, and make sure any blood-derived or cell-based products come from carefully screened donors. AAEP also recommends routine testing of donor horses used for biologic products.

Because non-biologic spread is still being studied, prevention is not perfect. If a horse on the property develops unexplained hepatitis, your vet may suggest monitoring stablemates, reviewing recent treatments, and tightening general biosecurity. Seasonal patterns have raised concern about possible insect involvement, so sensible fly control may be part of a broader risk-reduction plan even though that route is not fully proven.

For pet parents, prevention is really about asking better questions before a product is given. A short conversation with your vet about screening, sourcing, and alternatives can meaningfully lower risk.